Advertisement
AXON vs INSM
Which Stock Would AI Choose? Axon Enterprise (AXON) vs. Insmed (INSM) Stock Comparison
Key Takeaways
- AXON has demonstrated consistent revenue expansion in public safety technology, with recent quarters showing double-digit growth in software and connected devices segments.
- INSM reported positive 12-month data on its TPIP (Treprostinil Palmitil Inhalation Powder) candidate for pulmonary arterial hypertension, alongside ongoing commercialization of Brinsupri and ARIKAYCE.
- Both stocks have experienced volatility in recent market activity, with AXON trading near mid-range levels after earlier highs and INSM showing recovery attempts following launch-related concerns.
- Sector exposure differs sharply: AXON operates in industrial goods and law enforcement tech, while INSM focuses on biotechnology and rare respiratory diseases.
- Analyst sentiment remains generally constructive for both, with multiple price target adjustments noted in recent weeks reflecting growth expectations.
- Relative positioning highlights trade-offs between AXON’s established recurring revenue streams and INSM’s pipeline-driven upside potential.
Introduction
This comparison examines AXON and INSM to provide traders and investors with an objective view of their relative performance and positioning in the current market. Axon Enterprise delivers public safety solutions, while Insmed develops therapies for serious and rare diseases. The analysis is relevant for those evaluating exposure across technology-enabled industrials and biotechnology sectors, particularly participants monitoring momentum, catalysts, and risk profiles over multi-week horizons. Broader references to recent market activity allow the insights to remain applicable beyond immediate trading sessions.
Axon Enterprise (AXON) Overview and Recent Performance
Axon Enterprise provides public safety technology, including conducted energy devices under the TASER brand, body-worn cameras, and cloud-based evidence management software. The company serves law enforcement and government clients through hardware and recurring software-as-a-service offerings. In recent market activity, AXON has shown resilience with revenue growth in both connected devices and software segments. Performance has been influenced by strong bookings trends, analyst upgrades, and integration of new technologies such as real-time crime center solutions. Broader sentiment reflects steady demand in public safety markets, though valuation metrics and cost pressures have contributed to periodic share price fluctuations over recent weeks.
Insmed (INSM) Overview and Recent Performance
Insmed is a biopharmaceutical company focused on therapies for serious and rare diseases, with emphasis on respiratory conditions. Its portfolio includes commercial products such as Brinsupri and ARIKAYCE, alongside pipeline candidates like TPIP for pulmonary arterial hypertension. Recent market activity for INSM has featured volatility tied to commercialization progress and clinical updates. Positive 12-month extension data for TPIP supported sentiment in recent periods, while launch dynamics for newer assets introduced some uncertainty. Broader influences include analyst coverage highlighting pipeline durability and revenue trajectories from existing treatments, resulting in mixed share price responses over recent weeks.
Trending AI Robots
Tickeron maintains a curated selection of AI trading bots on its Trending AI Robots page. The platform offers hundreds of AI trading bots that operate across thousands of different tickers, each employing distinct trading styles, strategies, timeframes, and performance statistics. Only those demonstrating the strongest alignment with prevailing market conditions receive placement in the trending section. Available bots display varied metrics, including win rates, drawdowns, and return profiles that can range widely depending on strategy and timeframe. This diversity allows users to explore options suited to different risk tolerances and market environments. Readers interested in automated approaches may review the full selection on the Trending AI Robots page.
Head-to-Head Comparison
AXON and INSM operate in fundamentally different business models, with AXON generating recurring revenue from software and hardware in the public safety sector and INSM pursuing product revenue and pipeline advancement in biotechnology. Growth drivers for AXON center on adoption of evidence management platforms and device upgrades, while INSM relies on clinical data readouts and commercialization milestones. Recent momentum has favored stability in AXON’s established markets compared with INSM’s sensitivity to trial outcomes and launch pacing. Risk factors include regulatory and competitive pressures for both, though INSM carries higher binary outcome exposure typical of development-stage assets. Sector sentiment for industrials has been more consistent than for biotechs, where valuation debates around pipeline potential remain active.
Tickeron AI Verdict
Tickeron’s AI models may currently assign relatively higher favorability to AXON on the basis of more consistent trend patterns and revenue visibility in recent market activity. INSM presents notable catalysts from clinical updates that could influence positioning, though with greater variability in outcomes. The assessment remains probabilistic and reflects observable factors such as trend consistency and relative sector stability rather than forward projections.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a Hold and INSM is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green whileINSM’s FA Score has 0 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- INSM’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 4 TA indicator(s) are bullish while INSM’s TA Score has 5 bullish TA indicator(s).
- AXON’s TA Score: 4 bullish, 5 bearish.
- INSM’s TA Score: 5 bullish, 5 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а -1.56% price change this week, while INSM (@Biotechnology) price change was -1.29% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was -0.19%. For the same industry, the average monthly price growth was -8.76%, and the average quarterly price growth was -10.50%.
The average weekly price growth across all stocks in the @Biotechnology industry was -4.78%. For the same industry, the average monthly price growth was -3.76%, and the average quarterly price growth was +1901.89%.
Reported Earning Dates
AXON is expected to report earnings on Aug 05, 2026.
INSM is expected to report earnings on Aug 06, 2026.
Industries' Descriptions
@Aerospace & Defense (-0.19% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (-4.78% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| AXON | INSM | AXON / INSM | |
| Capitalization | 40.5B | 23.2B | 175% |
| EBITDA | 320M | -1.08B | -30% |
| Gain YTD | -11.549 | -38.566 | 30% |
| P/E Ratio | 202.56 | N/A | - |
| Revenue | 2.98B | 820M | 364% |
| Total Cash | 737M | 1.22B | 60% |
| Total Debt | 1.83B | 580M | 315% |
AXON | INSM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 87 Overvalued | 76 Overvalued | |
PROFIT vs RISK RATING 1..100 | 64 | 63 | |
SMR RATING 1..100 | 81 | 100 | |
PRICE GROWTH RATING 1..100 | 49 | 62 | |
P/E GROWTH RATING 1..100 | 35 | 100 | |
SEASONALITY SCORE 1..100 | 90 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
INSM's Valuation (76) in the Biotechnology industry is in the same range as AXON (87). This means that INSM’s stock grew similarly to AXON’s over the last 12 months.
INSM's Profit vs Risk Rating (63) in the Biotechnology industry is in the same range as AXON (64). This means that INSM’s stock grew similarly to AXON’s over the last 12 months.
AXON's SMR Rating (81) in the Biotechnology industry is in the same range as INSM (100). This means that AXON’s stock grew similarly to INSM’s over the last 12 months.
AXON's Price Growth Rating (49) in the Biotechnology industry is in the same range as INSM (62). This means that AXON’s stock grew similarly to INSM’s over the last 12 months.
AXON's P/E Growth Rating (35) in the Biotechnology industry is somewhat better than the same rating for INSM (100). This means that AXON’s stock grew somewhat faster than INSM’s over the last 12 months.
| AXON | INSM | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 59% | 3 days ago 66% |
| Stochastic ODDS (%) | 3 days ago 75% | 3 days ago 77% |
| Momentum ODDS (%) | 3 days ago 70% | 3 days ago 71% |
| MACD ODDS (%) | 3 days ago 77% | 3 days ago 70% |
| TrendWeek ODDS (%) | 3 days ago 68% | 3 days ago 72% |
| TrendMonth ODDS (%) | 3 days ago 73% | 3 days ago 74% |
| Advances ODDS (%) | 3 days ago 74% | 18 days ago 71% |
| Declines ODDS (%) | 5 days ago 70% | 11 days ago 73% |
| BollingerBands ODDS (%) | 3 days ago 70% | 3 days ago 73% |
| Aroon ODDS (%) | 3 days ago 75% | 3 days ago 73% |
Advertisement
AXON and
Correlation & Price change
A.I.dvisor indicates that over the last year, AXON has been loosely correlated with TECH. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if AXON jumps, then TECH could also see price increases.
| Ticker / NAME | Correlation To AXON | 1D Price Change % | ||
|---|---|---|---|---|
| AXON | 100% | +2.12% | ||
| TECH - AXON | 61% Loosely correlated | -0.24% | ||
| VCYT - AXON | 58% Loosely correlated | -2.19% | ||
| BEAM - AXON | 57% Loosely correlated | -3.13% | ||
| SEER - AXON | 56% Loosely correlated | -3.90% | ||
| ADPT - AXON | 56% Loosely correlated | -0.18% | ||
More | ||||
INSM and
Correlation & Price change
A.I.dvisor indicates that over the last year, INSM has been closely correlated with CNTN. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if INSM jumps, then CNTN could also see price increases.
| Ticker / NAME | Correlation To INSM | 1D Price Change % | ||
|---|---|---|---|---|
| INSM | 100% | -0.46% | ||
| CNTN - INSM | 74% Closely correlated | -5.83% | ||
| TRDA - INSM | 51% Loosely correlated | -3.31% | ||
| ENGN - INSM | 48% Loosely correlated | -3.70% | ||
| AXON - INSM | 40% Loosely correlated | +2.12% | ||
| ARRY - INSM | 40% Loosely correlated | -5.42% | ||
More | ||||